Supplement Bioavailability: Why Clinically Studied Ingredients Still Fail

Written by Kalon Executive Search & Saanroo

When it comes to supplements, how much actually reaches the cells matters more than how much is in the capsule. A curcumin extract can have dozens of studies behind it and still fall flat once it’s on a shelf. The same story holds for berberine, omega-3s, resveratrol, PEA, CoQ10, and oleoylethanolamide (OEA). The science on the molecule holds up fine. The capsule can still let the person down.

That’s bioavailability. It’s not about whether an ingredient made it into the bottle. It’s about whether enough of it is actually absorbed, survives digestion, reaches circulation, and shows up at the tissue or cell where it’s supposed to do something.

Clinically Studied vs. Clinically Delivered: The Bioavailability Gap

Most active brands face the same problem: they’re poorly water-soluble, poorly absorbed, or both. Curcumin, lutein, resveratrol, CoQ10, omega-3s — all fat-soluble — don’t mix well with the watery environment inside your gut. They clump together. They just sit there. Only a small fraction ever crosses the intestinal wall.

Other ingredients don’t even make it that far before something breaks them down. Take OEA. Your body naturally produces it after eating, and it plays a role in satiety signaling, including pathways connected to GLP-1. OEA is degraded during the intestinal wall’s own absorption/first-pass step, after it arrives but before it circulates to where it is supposed to act. Getting OEA into a bottle is the easy part. Getting it to where it works is another story.

Berberine faces a similar issue. Its oral bioavailability is often cited as under 1%, meaning most of a given dose never reaches systemic circulation in any meaningful way. That doesn’t make berberine pointless; some of its effects occur right in the gut. But it also means a large number on the label can translate to a small amount actually delivered.

Then there’s the final stretch of the journey, which matters just as much. Getting an ingredient into the bloodstream isn’t the finish line. CoQ10’s real job happens inside mitochondria, where it helps shuttle electrons during energy production. Curcumin and resveratrol are valued for their potential cellular effects — antioxidant activity and inflammatory signaling. None of that happens if the molecule never leaves the GI tract, or if it barely registers in plasma once it does.

Why supplements quietly underperform:

• The dose on the label looks clinical. The dose your body absorbs isn’t.
• Particles clump together in the stomach instead of dispersing the way they need to.
• Fat-soluble actives never form the micelles required for uptake.
• Enzymes break down the ingredient before it reaches its target.

Brands respond by increasing the dose. This leads to larger pills, more GI discomfort, and results that still don’t add up.

It’s worth distinguishing two terms people often use interchangeably. Absorption is the process of getting something into the bloodstream. Bioavailability is the percentage of what you actually swallowed that the body can use. Delivery systems can close that gap.

Matching Delivery Systems to the Ingredient’s Absorption Barrier

Saanroo’s long-time delivery-technology partner, Pharmako Biotechnologies, develops platforms tailored to the specific failure mode of the ingredient. This includes solubility, dispersion, permeability, and stability. They don’t make a general “enhanced absorption” claim; the leading systems are based on human pharmacokinetic and clinical research.

AquaCelle® is a self-micro-emulsifying delivery system (SMEDDS). In the stomach, it forms micelles on its own. Micelles are small fat-in-water structures that the body uses to absorb dietary fats. This is why it is designed for oily, lipophilic active ingredients such as omega-3s, CoQ10, and lutein.

In a published study on CoQ10, the AquaCelle preparations produced increases in CoQ10 that were roughly 2.4 to 3 times greater than those with standard CoQ10, depending on the format. In a fish-oil study using equal doses of EPA and DHA, AquaCelle achieved an absorption of total EPA and DHA (AUC0–24h) about 6.1 times higher than the standard control, with Cmax approximately 3.7 times greater. For mitochondrial nutrients such as CoQ10, that rise in plasma levels makes the difference between a label claim and a real chance of the nutrient reaching the organelle that uses it.

LipiSperse® works differently. It’s a cold-water dispersion technology for solid, hydrophobic powders. It lowers interfacial tension, preventing particles from clumping in water-based environments. A practical benefit is the high loading level, since 10% LipiSperse can contain as much as 90% active ingredient, meaning the consumer does not end up swallowing mostly carrier. This technology forms the basis of several Saanroo ingredients.

Pharmako also uses liposomal and pro-liposomal methods when the issue is membrane permeation and cellular uptake, not merely gut dispersion. The idea is not that each ingredient must be enclosed in a liposome. It’s that the delivery system should match the molecule’s properties.

How Does Bioavailability Improve When Delivery is Built In?

HydroCurc® (curcumin + LipiSperse®)

In a randomized, double-blind pharmacokinetic study published in the European Journal of Nutrition, 750 mg of curcuminoids paired with LipiSperse produced significantly higher plasma curcuminoid levels than the same extract without LipiSperse — 807 vs. 318 ng/mL in the crossover arm. Same molecule. Different delivery. Different blood levels. That is the opposite of a failure mode.

Levagen®+ (PEA + LipiSperse®)

Palmitoylethanolamide is fat-soluble and poorly absorbed in its standard form. A pharmacokinetic study showed that Levagen+ increased plasma PEA levels about 1.75 times more than a standard PEA formulation. Subsequent clinical research used that bioavailable form in areas such as muscle recovery. In a small crossover trial involving female students, it was used to assess stress-related measures. The delivery method made it possible to achieve a usable oral dose.

VeriSperse® (trans-resveratrol + LipiSperse®)

A human study found roughly double the absorption (AUC) and a threefold increase in Cmax for resveratrol conjugates, compared with the same 150 mg dose without LipiSperse. Resveratrol’s reputation has never kept pace with its oral availability. Dispersion is what keeps most of that capsule from going to waste.

Trpti™ (OEA + LipiSperse®)

Trpti from Saanroo uses LipiSperse so that OEA can reach the sites of action in the intestine rather than being broken down first. In a 12-week randomized, double-blind, placebo-controlled study of 57 adults with a BMI between 30 and 40 who took 300 mg per day, Trpti was linked to changes in the microbiome. These changes include enrichment of Akkermansia muciniphila and Faecalibacterium prausnitzii, along with indicators of gut barrier integrity and inflammatory tone, and an upward trend in GLP-1. That doesn’t amount to ‘more OEA on the label’. OEA has reached the point where the biological effects take place.

BioBerb® (berberine + LipiSperse®)

BioBerb is water-dispersible berberine produced by Pharmako from Berberis aristata and standardized for berberine content. It is also formulated with LipiSperse to improve dispersion and allow for lower, more practical doses when taken in capsule or drink form. A randomized, double-blind study on BioBerb reportedly showed 70% higher total berberine absorption and 80% higher peak concentration than standard berberine. Standard berberine absorption is well known to be difficult and combining it with a proven dispersion system makes this metabolic ingredient suitable for formulation without requiring a large number of tablets.

From Bloodstream to Cell

Mitochondria produce the cell’s energy because they convert nutrients and oxygen into ATP. CoQ10 is involved in the electron-transport process because it is located in the inner mitochondrial membrane. If CoQ10 does not increase in the plasma when taken orally, the mitochondria will not receive a usable amount.

Other substances are not mitochondrial vitamins, but they still have a cellular address through cell membranes, gut-lining receptors, and inflammatory pathways within the cell. AquaCelle and LipiSperse don’t ‘magically’ insert curcumin into the mitochondria. Instead, they overcome previous bottlenecks: dispersion, micelle formation, and absorption. This allows a clinically relevant dose to appear in the blood, making it available to tissues.

This sequence is the honest version of “reaches the cell”:

• Survive the gut.
• Disperse instead of clumping.
• Enter circulation at a meaningful level.
• Become available to the tissue or organelle that uses it.

Skip step 2 or 3, and clinical literature on the raw ingredient doesn’t transfer to the product in the bottle.

What This Means for Brands and Consumers

So why do clinically studied ingredients fail in the market? The dose and form used in the study do not match those in the final product. Delivery systems are designed so the dose in the body resembles the dose used in the study, not just the dose shown on the Supplement Facts panel.

Saanroo’s model is the practical answer: pair a characterized active with a Pharmako system built to address that active’s weakness. HydroCurc, Levagen+, VeriSperse, Trpti, BioBerb, and AquaCelle Omega-3 or CoQ10 formats are examples of the same idea: proof at the molecular level, plus proof that the molecule can get in.

The appropriate question isn’t simply whether this ingredient has been studied. Instead, it is whether, in this form and at this dose, enough of it reaches the site where it needs to act.

These statements have not been evaluated by the Food and Drug Administration. These ingredients are not intended to diagnose, treat, cure, or prevent any disease. Individual results vary. Study designs, doses, and populations differ; product claims should be based on the specific evidence on file for each branded ingredient.